Medical Doctor Program year 2024 Reported 2020–2024 Source: CMS Open Payments, 2026 publication

Marlon Mathews

Sports Medicine Palm Springs, CA Medical Doctor

NPI 1639332422 CMS profile 2126613

275 N El Cielo Rd # D-402, Palm Springs, CA 92262

Open in the dashboard

General payments

$115,718

43 records reported · program years 2020–2024

Research payments

$0

Paid to them · None reported · program years 2020–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Marlon Mathews of Palm Springs, CA is reported in the CMS Open Payments database as having received $115,718 across 43 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $30,750 11
2023 General $24,000 8
2022 General $33,733 12
2021 General $25,860 10
2020 General $1,375 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marlon Mathews
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Marlon Mathews were reported at $0. Among 1,257 Sports Medicine profiles paid that year, the median was $114 and the middle half received between $39 and $293.

Show as a table
Year Marlon Mathews Sports Medicine median Middle half National median
2019 $0 $119 $35–$362 $163
2020 $1,375 $77 $24–$275 $114
2021 $25,860 $104 $28–$340 $132
2022 $33,733 $94 $31–$272 $149
2023 $24,000 $91 $34–$271 $160
2024 $30,750 $126 $38–$294 $164
2025 $0 $114 $39–$293 $169

Breakdown

Who paid General payments · program years 2020–2024
  1. Takeda Pharmaceuticals U.S.A., Inc. $115,718 43 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2024
  1. Consulting Fee $115,718 43 payments

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

2,774

Median for Family Practice: 1,826

Drug cost

$33,871

Median for Family Practice: $120,094

Branded share of claims

22%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 13 $9,451
Paxlovid Nirmatrelvir/Ritonavir Brand 23 $7,145
Albuterol Sulfate Hfa Albuterol Sulfate Brand 99 $2,470
Doxycycline Hyclate Generic 247 $1,541
Methylprednisolone Generic 277 $1,394
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 90 $1,159
Ofloxacin Generic 38 $998
Diclofenac Sodium Generic 46 $946
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 140 $868
Celecoxib Generic 93 $760

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$19,124

Of which drugs: $211

Medicare patients

200

Average age 75

Services billed

689

114 women, 86 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 56%
Diabetes 30%
Chronic kidney disease 30%
Depression 28%
Ischemic heart disease 26%
COPD 22%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ketorolac tromethamine, per 15 mg J1885 Office 21 45 $21

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

43 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record